Showing 1 to 1 of 1 results
europe.chinadaily.com.cn
🌐 85% Global Worthiness


Sanofi's Tzield Approved in China for Type 1 Diabetes Prevention
Sanofi's Tzield, an injection delaying type 1 diabetes progression, received approval in China, offering a three-year delay to stage 3 for eligible patients, impacting 600,000 individuals.
Sanofi's Tzield Approved in China for Type 1 Diabetes Prevention
Sanofi's Tzield, an injection delaying type 1 diabetes progression, received approval in China, offering a three-year delay to stage 3 for eligible patients, impacting 600,000 individuals.
Progress
36% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results